Hepatic Encephalopathy: Lactulose or Polyethylene Glycol (H.E.L.P.)
Hepatic Encephalopathy: Lactulose or Polyethylene Glycol (H.E.L.P.)
The purpose of this study is to evaluate whether the use of polyethylene glycol is superior
 and more safe in treating hepatic encephalopathy compared to lactulose and also to determine
 if treatment with polyethylene glycol will reduce the duration of hospital stay.
Hepatic encephalopathy is the occurrence altered level of consciousness as a result of
 cirrhosis and liver failure. Main treatment goal for hepatic encephalopathy is to eliminate
 the precipitating factor and to decrease circulating ammonia level. Current standard for
 treating HE is treatment with Lactulose. Lactulose are metabolized by colonic bacteria to
 byproducts which cause catharsis and reduces pH, thereby inhibiting ammonia absorption.
 However, there is limited evidence available to demonstrate the efficacy. Studies on animal
 model have suggested that polyethylene glycol 3350-electrolyte solution (GOLYTELY) is
 effective in clearing gut bacteria and reducing the ammoniagenesis in colon. Recently
 published study by Robert Rahimi, University of Texas Southwestern Medical Center found that
 polyethylene glycol is more effective in improving HE over the first 24 hours compared to
 lactulose and also may reduce duration of hospital stay.
Inclusion Criteria:

 -  Age 18 - 80

 -  Male and female of all races and ethnicities

 -  Cirrhosis of any cause

 -  Any grade of hepatic encephalopathy (1-4)

 -  Representatives have to be willing to comply with all protocol procedures and to
 understand, sign and date an informed consent document and authorize access to
 protected health information on the subject's behalf

 Exclusion Criteria:

 -  Acute liver failure

 -  Prisoners

 -  Structural brain lesions (as indicated by CT and confirmed by neurological exam)

 -  Other causes of altered mental status

 -  Previous use of rifaximin or neomycin within last 7 days

 -  Pregnancy

 -  Serum Na <125 MEq/liter

 -  Receiving more than 1 dose (30 cc) of lactulose prior to enrollment

 -  Uncontrolled infection with hemodynamic instability requiring vasopressors.